Kornam

Terazosin, the active ingredient in Kornam, is an alpha‑1 adrenergic receptor antagonist presented as an oral dosage form for oral use. It is prescribed to manage hypertension and to alleviate urinary symptoms associated with benign prostatic hyperplasia in adult patients. GNH USA supplies Kornam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity from manufacturing to delivery through validated cold‑chain processes where applicable.

Terazosin is used in cardiovascular and urological conditions that involve alpha‑1 mediated smooth‑muscle tone.

- Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. - Benign prostatic hyperplasia (BPH): relaxes prostate and bladder neck smooth muscle to improve urinary flow. - Essential hypertension: assists patients in achieving target blood pressure goals as part of antihypertensive therapy.

Terazosin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Syncope: sudden loss of consciousness. - Priapism: prolonged, painful erection requiring urgent medical attention.

When prescribing Terazosin, clinicians should observe several safety considerations to reduce risk.

- Blood pressure monitoring: check supine and standing readings before and during therapy. - Orthostatic hypotension: advise patients to rise slowly from sitting or lying positions. - Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction. - Concomitant alpha‑blockers: avoid combining with other alpha‑1 antagonists to prevent additive hypotensive effects. - Renal impairment: assess kidney function and adjust dose if necessary. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Terazosin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., prazosin, doxazosin): may cause excessive hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): increase risk of severe blood pressure drop. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise terazosin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: additive effect on blood pressure, monitor electrolytes. - ACE inhibitors or ARBs: combined antihypertensive effect may require dose titration. - Beta‑blockers: may enhance overall cardiovascular depression. - NSAIDs: can blunt antihypertensive response, watch blood pressure control.